Get started

Pfizerlong

PFE Pfizer retracement completed. Buy opportunity?I warned you about the retracement in the last post: Look, it`s not trading advice, but the retracement of Pfizer seems completed and now it`s ready for another leg up! They`ve invented the most important vaccine of out time, let`s not diminish their merits. If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NYSE:PFELong
by TopgOptions
19
Pfizer: Wide Moat and Interesting Ichimoku CloudsAfter the massive price drop at the end of July, Pfizer is pivoting its strategy selling Upjohn Unit to a new joint venture with Mylan and focusing on the new BioPharma business (mainly focusing on Ibrance, Xtandi, Inlyta, etc.). The new strategy provides Pfizer with a wide economic moat. I think the market currently undervalues the stock. The current price is above Ichimoku Green Cloud, and it coincides with the Lagging Span. I will expect a bullish progression of the price in the long term with the market correctly evaluating the new strategy. However, I see a risk of profit-taking in the next sessions anyhow, not so significant to let the stock test the upper support of the green cloud. Please, note that this analysis applies to long term positions. Don't forget to support this idea, if you liked it, and to follow me, here on TradingView. If you have another trading plan, please share in comments! Investing Fellow Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor.
NYSE:PFELong
by Investing_Fellow
Pfizer: Steady buy in a volatile market. Target $48.Pfizer has been among the top stocks during this year's market correction. Recently it has been trading within a 1D Channel Up which just priced its Higher Low (RSI = 48.610, MACD = 0.230, highs/Lows = 0.0000). Assuming it will print an identical Higher High next on +3.60%, we have a long target of $48.00 by mid January. Note that Pfizer also packs a decent quarterly dividend (yields 3.1%). ** If you like our free content follow our profile (www.tradingview.com) to get more daily ideas. ** Comments and likes are greatly appreciated.
NYSE:PFELong
by InvestingScope